Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
COSTS AND EXPENSES:    
Research and development $ 2,124,060 $ 1,856,880
General and administrative 1,329,467 955,356
Total costs and expenses 3,453,527 2,812,236
LOSS FROM OPERATIONS (3,453,527) (2,812,236)
OTHER INCOME (EXPENSE):    
Loss on revaluation of derivative warrants (26,950) (82,475)
Interest income, net 4,654 3,387
Total other income (expense), net (22,296) (79,088)
NET LOSS $ (3,475,823) $ (2,891,324)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.21) $ (0.24)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 16,808,189 12,010,284